CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+25.17%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.34B
AUM Growth
+$1.34B
(+32%)
Cap. Flow
+$217M
Cap. Flow
% of AUM
16.15%
Top 10 Holdings %
Top 10 Hldgs %
71.54%
Holding
39
New
3
Increased
13
Reduced
4
Closed
3
Top Buys
| 1 |
Standard BioTools
LAB
|
$165M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$24.4M |
| 3 |
Avidity Biosciences
RNA
|
$23.2M |
| 4 |
Veracyte
VCYT
|
$19M |
| 5 |
Exact Sciences
EXAS
|
$15.9M |
Top Sells
| 1 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
$31.9M |
| 2 |
Illumina
ILMN
|
$8.93M |
| 3 |
Pliant Therapeutics
PLRX
|
$8.6M |
| 4 |
Fate Therapeutics
FATE
|
$7.67M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$7.45M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$7.1B
| $181M | 13.46% | 5,617,599 -97,176 | -2% | -$3.13M |
|
|
2
Standard BioTools
LAB
$481M
| $168M | 12.47% | 61,907,605 +60,707,605 | +5,059% | +$165M |
|
3
BioLife Solutions
BLFS
$1.2B
| $162M | 12.01% | 8,707,165 | – | – |
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $138M | 10.29% | 1,069,000 +62,500 | +6% | +$8.09M |
|
5
Relay Therapeutics
RLAY
$619M
| $61.6M | 4.58% | 7,423,574 +35,631 | +0.5% | +$296K |
|
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $53.5M | 3.98% | 358,000 +163,000 | +84% | +$24.4M |
|
|
7
Avidity Biosciences
RNA
$5.99B
| $53.2M | 3.96% | 2,084,841 +909,091 | +77% | +$23.2M |
|
8
Intellia Therapeutics
NTLA
$1.22B
| $51.6M | 3.83% | 1,875,000 +425,000 | +29% | +$11.7M |
|
9
Structure Therapeutics
GPCR
$1.11B
| $47.9M | 3.56% | 1,116,867 +25,000 | +2% | +$1.07M |
|
|
10
Exact Sciences
EXAS
$8.98B
| $44.9M | 3.34% | 650,000 +230,000 | +55% | +$15.9M |
|
|
VERV
11
DELISTED
Verve Therapeutics
VERV
| $40.6M | 3.02% | 3,059,094 +50,000 | +2% | +$664K |
|
12
Tenaya Therapeutics
TNYA
$184M
| $35.2M | 2.62% | 6,732,971 +351,594 | +6% | +$1.84M |
|
|
13
Illumina
ILMN
$15.8B
| $34.1M | 2.53% | 248,000 -65,000 | -21% | -$8.93M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $31M | 2.3% | 326,378 | – | – |
|
15
GeneDx Holdings
WGS
$3.72B
| $28.6M | 2.13% | 3,136,411 +40,900 | +1% | +$373K |
|
16
Neurogene
NGNE
$264M
| $26.7M | 1.99% | 524,616 | – | – |
|
17
Denali Therapeutics
DNLI
$2.23B
| $26.7M | 1.98% | 1,300,000 | – | – |
|
|
18
4D Molecular Therapeutics
FDMT
$288M
| $25.5M | 1.89% | 800,000 -233,811 | -23% | -$7.45M |
|
19
Beam Therapeutics
BEAM
$1.66B
| $22.3M | 1.66% | 675,000 +147,000 | +28% | +$4.86M |
|
|
20
Veracyte
VCYT
$2.39B
| $19M | 1.41% | +857,904 | New | +$19M |
|
|
21
Pliant Therapeutics
PLRX
$101M
| $14.9M | 1.11% | 1,000,000 -577,108 | -37% | -$8.6M |
|
22
Century Therapeutics
IPSC
$42.5M
| $13.4M | 1% | 3,206,380 | – | – |
|
|
TSVT
23
DELISTED
2seventy bio
TSVT
| $10.7M | 0.8% | 2,000,000 +817,377 | +69% | +$4.37M |
|
24
AbCellera Biologics
ABCL
$1.25B
| $10.7M | 0.79% | 2,360,129 | – | – |
|
25
Tango Therapeutics
TNGX
$747M
| $9.44M | 0.7% | 1,188,349 | – | – |
|